Phenytoin NCT07801157 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Completed

Recruitment status

24

Planned enrollment

2025-12-01

Primary-completion proxy

Executive view

NCT07801157 evaluates Phenytoin in Squamous cell carcinoma of the oral cavity. The disclosed sponsor is Mansoura University, the design is Interventional, and the geographic footprint is Egypt. The first listed primary endpoint is Postoperative Wound Healing Score, assessed over Postoperative day 1, week 1, week 2, month 1, month 3, and month 6.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07801157 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Squamous cell carcinoma of the oral cavity landscape. Drug & Asset MCP drug_fetch was queried for Phenytoin, while Company & Deal Intelligence MCP organization_fetch was queried for Mansoura University.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07801157	Phenytoin	Not Applicable / Completed	Mansoura University	Egypt	Postoperative Wound Healing Score Postoperative day 1, week 1, week 2, month 1, month 3, and month 6	2025-12-01
NCT07802977	Dexamethasone Sodium Phosphate	Phase 1 / Completed	University of California, Davis	United States	Number of Missed or Delayed Days of Radiation Therapy Due to Steroid Injection From first steroid injection through completion of radiation therapy…	2022-07-30
NCT07799077	Paclitaxel	Phase 2 / Not yet recruiting	The Fourth Hospital of Hebei Medical University	China	Pathological Complete Response (pCR) rate Assessed via surgical pathology (4-6 weeks post-neoadjuvant therapy)	2027-12-31
NCT07796789	Megestrol Acetate	Phase 3 / Recruiting	Sun Yat-Sen University	China	Proportion of Patients With >5% Weight Loss From Baseline at Day 28 After Completion of Radiotherapy Day 28 after completion of radiotherapy	2027-08-30
NCT07797881	PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical)	Phase 2 / Not yet recruiting	Sichuan Baili Pharmaceuticals Co.,Ltd	China	Complete Response Rate(CRR) Up to approximately 24 months	2030-12-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07801157 is a Not Applicable, completed study with 24 planned participants. Allocation is Randomized, masking is Single, and the intervention model is Parallel Assignment.

The primary endpoint is “Postoperative Wound Healing Score” over “Postoperative day 1, week 1, week 2, month 1, month 3, and month 6.” The retrieved endpoint description is: Wound healing and infection assessed using the Pippi modification of the Landry Wound Healing Index, scored from 0 (worst healing) to 6 (complete healing)..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 24 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

4 recent result records were selected as contextual evidence for Squamous cell carcinoma of the oral cavity. These records do not establish direct evidence for NCT07801157 unless the registration number matches.

Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas

Phase 1/2; n=26; Safety of Abemaciclib + Ramucirumab = 10 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04921904

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Phase 2; n=9; CR = 0 participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05119296

M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention

Phase 2; n=34; Histologic Response to Metformin: P-Value = 0.715; Histologic Response to Metformin: P-Value = 0.715 Source: https://clinicaltrials.gov/ct2/show/results/NCT05237960

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Phenytoin is indexed as Small molecule drug with Nav1.1 x Nav1.5 biology and a global stage of Approved. The asset profile lists Pfizer Inc. as an originator or developer.

Mansoura University is indexed in Egypt with the website http://www.mans.edu.eg. Mansoura University is an Egyptian university to establish and develop a number of Management Information Systems. The record lists 42 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Phenytoin is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07801157
Protocol source: https://clinicaltrials.gov/study/NCT07801157
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Phenytoin in Squamous cell carcinoma of the oral cavity is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Postoperative Wound Healing Score and 2025-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP